Experienced in Cranioectodermal Dysplasia

Dr. Bart P. Leroy

Ophthalmology
34th & Civic Center Blvd, Children's Hospital Of Philadelphia, 
Philadelphia, PA 
Experienced in Cranioectodermal Dysplasia
34th & Civic Center Blvd, Children's Hospital Of Philadelphia, 
Philadelphia, PA 
OverviewInsuranceLocationsClinical Research

Overview

Bart Leroy is an Ophthalmologist in Philadelphia, Pennsylvania. Dr. Leroy is rated as an Experienced provider by MediFind in the treatment of Cranioectodermal Dysplasia. His top areas of expertise are Leber Congenital Amaurosis, Retinopathy Pigmentary Mental Retardation, Late-Onset Retinal Degeneration, Vitrectomy, and Cataract Removal.

His clinical research consists of co-authoring 172 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Cranioectodermal Dysplasia.

Specialties
Ophthalmology
Licenses
Ophthalmology in PA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

34th & Civic Center Blvd, Children's Hospital Of Philadelphia, Philadelphia, PA 19104

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Efficacy and Safety of Bilateral Intravitreal Injection of GS010: A Randomized, Double-Masked, Placebo-Controlled Trial in Subjects Affected With G11778A ND4 Leber Hereditary Optic Neuropathy for Up to One Year
Efficacy and Safety of Bilateral Intravitreal Injection of GS010: A Randomized, Double-Masked, Placebo-Controlled Trial in Subjects Affected With G11778A ND4 Leber Hereditary Optic Neuropathy for Up to One Year
Enrollment Status: Completed
Publish Date: August 26, 2025
Intervention Type: Drug, Genetic
Study Phase: Phase 3
Translational Stem Cell Research in Ophthalmology - Regenerating the Anterior Cornea Through Standardized Transplantation of Limbal Epithelial Stem Cells: a Phase II Multicenter Trial
Translational Stem Cell Research in Ophthalmology - Regenerating the Anterior Cornea Through Standardized Transplantation of Limbal Epithelial Stem Cells: a Phase II Multicenter Trial
Enrollment Status: Completed
Publish Date: January 15, 2025
Intervention Type: Biological
Study Drug: Limbal epithelial stem cell graft
Study Phase: Phase 2
An Open-Label, Extension Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of QR-110 in Subjects With Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene
An Open-Label, Extension Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of QR-110 in Subjects With Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene
Enrollment Status: Terminated
Publish Date: October 15, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Evaluation of Light Sensitivity and Visual Acuity Changes as Consequence of Rigid Gas Permeable (RGP) Scleral Contact Lenses With a Passive Artificial Iris
Evaluation of Light Sensitivity and Visual Acuity Changes as Consequence of Rigid Gas Permeable (RGP) Scleral Contact Lenses With a Passive Artificial Iris
Enrollment Status: Terminated
Publish Date: April 27, 2022
Intervention Type: Device, Drug
Study Phase: Not Applicable
Double-masked, Randomized, Controlled, Multiple-dose Study to Evaluate Efficacy, Safety, Tolerability and Syst. Exposure of QR-110 in Leber's Congenital Amaurosis (LCA) Due to c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene
Double-masked, Randomized, Controlled, Multiple-dose Study to Evaluate Efficacy, Safety, Tolerability and Syst. Exposure of QR-110 in Leber's Congenital Amaurosis (LCA) Due to c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene
Enrollment Status: Active_not_recruiting
Publish Date: March 17, 2022
Intervention Type: Other, Drug
Study Phase: Phase 2/Phase 3
View 4 Less Clinical Trials

172 Total Publications

Short-Term Outcomes of Pediatric Patients With Mild Autosomal Recessive RPE65-Associated Retinal Dystrophy Treated With Voretigene Neparvovec.
Short-Term Outcomes of Pediatric Patients With Mild Autosomal Recessive RPE65-Associated Retinal Dystrophy Treated With Voretigene Neparvovec.
Journal: Translational vision science & technology
Published: August 04, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Leroy's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 7 Advanced Conditions
View All 26 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile